CEL-SCI Corporation Releases Letter to Shareholders

CEL-SCI Corporation Releases Letter to Shareholders

CEL-SCI CorporationGavin de Windt, 703-506-9460

Dear Fellow Shareholders:

As you know, we are currently running the largest ever Phase III clinical trial in head and neck cancer, a disease with a clear unmet medical need, with our investigational Multikine immunotherapy. The trial is currently being conducted in eight countries on three continents. It is designed so that if successfully completed the results will allow us to seek marketing approval in the key markets around the world. Our clinical study is the first trial in which immunotherapy is given before the standard of care (SOC) cancer therapies which consists of surgery, radiation and chemotherapy. Multikine is given prior to SOC because we believe that the stimulation of the immune system of a cancer patient after those cancer treatments is extremely difficult due to the known immuno-suppressive effects of surgery, radiation and chemotherapy. We are confident that our approach of early stimulation of the immune response will be proven to be correct.

This fall we took a big first step towards clearing a key hurdle in the Phase III trial. We were able to announce that our study’s Independent Data Monitoring Committee (IDMC), when reviewing the study data collected to date, advised that the study should be continued since the committee saw no safety signals which should end the study. We view this as a very positive event because safety and tolerability are key risks in all Phase III clinical trials. In October 2012 a Phase III study of a drug owned by Reata Pharmaceuticals and licensed to Abbott Labs for about $450 million was stopped due to safety problems. Several years ago Pfizer had to stop the Phase III study for its Lipitor successor at an estimated cost of $1 billion due to safety problems. In fact, a recent study estimated that up to 30% of Phase III trials fail on safety. So far our Phase III study results for the safety profile of this novel approach and investigational therapy regimen appear to track the results we obtained in our Phase II studies, and that is exactly what we wanted to see.

We are encouraged by the study’s IDMC findings, and as a result are now more aggressively expanding the study in the US and Western Europe. Our goal, now that the first IDMC interim safety review is behind us, is to further accelerate the patient recruitment by increasing the number of centers from the current 36 centers to, at least, the originally planned 50 centers. We are currently negotiating to bring on highly regarded US hospitals as well as European centers in multiple countries. We will keep you up-to-date on important developments occurring during the trial. We understand the desire of our shareholders to know as much as possible about our study’s progress, but ask you to understand that a lot of information cannot be shared publicly since it might bias the study results, which ultimately could lead to major problems in the Phase III trial and impede the possible approval of Multikine for commercial use by regulatory agencies.

Other company activities: Our L.E.A.P.S. collaborative study with the National Institutes for Allergy and Infectious Diseases (NIAID) on pandemic flu is also progressing well. The testing conducted by NIAID with our L.E.A.P.S. compounds has shown significant promise in animal models of the disease and has been submitted for publication. We believe that the data will potentially be very relevant when the next strain of drug resistant flu makes an appearance.

We are well into the final, and pivotal, study with Multikine designed to definitively prove that it will increase overall survival in a disease with a clear unmet medical need, where the last drug approval was about 50 years ago and where no other drug is in late stage development. Our goal is to replicate the promising results from our Phase II studies and so far that is what we are seeing. From here on we have a clear path to potentially enormous success. Few people ever get the chance to be part of something as significant as this. We thank you for your support during this Phase III clinical trial.


Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.